Display options
Cite
Boilève A, Hilmi M, Delaye M, et al. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?. Cancers (Basel). 2021;13(11)doi: 10.3390/cancers13112708.
Boilève, A., Hilmi, M., Delaye, M., Tijeras-Raballand, A., & Neuzillet, C. (2021). Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?. Cancers, 13(11), . https://doi.org/10.3390/cancers13112708
Boilève, Alice, et al. "Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?." Cancers vol. 13,11 (2021). doi: https://doi.org/10.3390/cancers13112708
Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?. Cancers (Basel). 2021 May 30;13(11). doi: 10.3390/cancers13112708. PMID: 34070929; PMCID: PMC8198554.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 May 30;13(11). doi: 10.3390/cancers13112708.

Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?.

Cancers

Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet

Affiliations

  1. Gustave Roussy, Département de Médecine Oncologique, 94805 Villejuif, France.
  2. GERCOR Group, 151 rue du Faubourg Saint-Antoine, 75011 Paris, France.
  3. Curie Institute, Département de Médecine Oncologique, 92210 Saint-Cloud, France.
  4. OncoMEGA, 75010 Paris, France.

PMID: 34070929 PMCID: PMC8198554 DOI: 10.3390/cancers13112708

Abstract

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapies. Treatment modalities are different yet partially overlapping between HCC and BTC. The complex molecular profile of BTC yields to several actionable therapeutic targets, contrary to HCC that remains the field of antiangiogenic drugs in non-molecularly selected patients. Immunotherapy is now validated in the first line in HCC in combination with bevacizumab, while clinical activity of single agent immunotherapy appears limited to a subset of patients in BTC, still poorly characterized, and combinations are currently under investigation. In this review, we provide a critical evaluation and grading of clinical relevance on (i) the main prognostic biomarkers in HCC and BTC, (ii) the main theragnostic biomarkers in both tumors, and lastly (iii) what is recommended in clinical practice.

Keywords: biliary tract cancers; biomarker; cholangiocarcinoma; hepatocellular carcinoma; immune checkpoint inhibitor; targeted therapy

References

  1. Cancer Res Treat. 2017 Jan;49(1):246-254 - PubMed
  2. Nat Genet. 2015 Sep;47(9):1003-10 - PubMed
  3. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  4. Oncologist. 2012;17(1):72-9 - PubMed
  5. Int J Cancer. 2020 Oct 15;147(8):2190-2198 - PubMed
  6. Lancet Oncol. 2020 Jun;21(6):796-807 - PubMed
  7. Cancer Imaging. 2014 Apr 22;14:14 - PubMed
  8. Lancet Oncol. 2019 Feb;20(2):282-296 - PubMed
  9. Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80 - PubMed
  10. Ann Transl Med. 2016 Dec;4(24):482 - PubMed
  11. Lancet Oncol. 2020 Jan;21(1):e29-e41 - PubMed
  12. Clin Gastroenterol Hepatol. 2013 Jan;11(1):13-21.e1; quiz e3-4 - PubMed
  13. Hepatology. 2014 Apr;59(4):1427-34 - PubMed
  14. Hepatology. 2016 Dec;64(6):2038-2046 - PubMed
  15. Eur J Cancer. 2018 Mar;92:11-19 - PubMed
  16. Liver Int. 2015 Aug;35(8):2001-8 - PubMed
  17. BMC Cancer. 2010 Nov 18;10:631 - PubMed
  18. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  19. Hepatology. 2008 May;47(5):1544-56 - PubMed
  20. Liver Int. 2019 May;39 Suppl 1:7-18 - PubMed
  21. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv238-iv255 - PubMed
  22. Lancet. 2017 Jun 24;389(10088):2492-2502 - PubMed
  23. BMC Cancer. 2002 May 03;2:10 - PubMed
  24. Hepatology. 2016 Jan;63(1):148-58 - PubMed
  25. J Hepatol. 2017 Nov;67(5):999-1008 - PubMed
  26. Lancet Oncol. 2018 Jul;19(7):940-952 - PubMed
  27. Int J Clin Exp Pathol. 2021 Feb 01;14(2):151-169 - PubMed
  28. Oncotarget. 2016 Oct 11;7(41):67142-67149 - PubMed
  29. J Int Med Res. 2021 Feb;49(2):300060520980646 - PubMed
  30. BMC Cancer. 2019 Feb 28;19(1):185 - PubMed
  31. Oncotarget. 2019 Jun 18;10(40):4018-4025 - PubMed
  32. J Surg Oncol. 2015 Aug;112(2):208-13 - PubMed
  33. Lancet Oncol. 2020 Oct;21(10):1353-1365 - PubMed
  34. J Surg Oncol. 2014 Sep;110(4):422-9 - PubMed
  35. Cureus. 2019 Jan 25;11(1):e3962 - PubMed
  36. J Hepatol. 2017 Oct;67(4):727-738 - PubMed
  37. Hepatology. 2007 Jan;45(1):42-52 - PubMed
  38. Br J Cancer. 2008 Jan 29;98(2):418-25 - PubMed
  39. J Gastrointest Oncol. 2012 Jun;3(2):97-104 - PubMed
  40. Sci Rep. 2017 Dec 5;7(1):16975 - PubMed
  41. Br J Cancer. 2019 Jul;121(2):117-124 - PubMed
  42. Cells. 2020 Jun 01;9(6): - PubMed
  43. Am J Med Sci. 2011 Jan;341(1):28-32 - PubMed
  44. Hepatology. 2012 Aug;56(2):769-75 - PubMed
  45. J Hepatol. 2019 Sep;71(3):616-630 - PubMed
  46. Hum Pathol. 2012 Oct;43(10):1552-8 - PubMed
  47. J Histochem Cytochem. 2014 Aug;62(8):547-55 - PubMed
  48. Scand J Surg. 2011;100(1):30-4 - PubMed
  49. Immunity. 2018 Mar 20;48(3):434-452 - PubMed
  50. J Gastrointest Cancer. 2016 Dec;47(4):502-505 - PubMed
  51. Ann Oncol. 2016 Sep;27(suppl 5):v28-v37 - PubMed
  52. Gastroenterology. 2013 Apr;144(4):829-40 - PubMed
  53. Cell. 2017 Jun 15;169(7):1327-1341.e23 - PubMed
  54. Gastroenterology. 2019 May;156(6):1731-1741 - PubMed
  55. World J Hepatol. 2016 Dec 18;8(35):1541-1546 - PubMed
  56. Gastroenterology. 2004 Nov;127(5 Suppl 1):S87-96 - PubMed
  57. Chin Clin Oncol. 2016 Oct;5(5):62 - PubMed
  58. World J Gastroenterol. 2008 Dec 14;14(46):7033-58 - PubMed
  59. Semin Liver Dis. 2014 Nov;34(4):456-64 - PubMed
  60. Nat Genet. 2013 Dec;45(12):1470-1473 - PubMed
  61. Pharmacol Ther. 2019 Apr;196:135-159 - PubMed
  62. Eur J Cancer. 2017 Dec;87:122-130 - PubMed
  63. Clin Cancer Res. 2012 Apr 15;18(8):2290-300 - PubMed
  64. Hepatology. 2012 Jun;55(6):1876-88 - PubMed
  65. Expert Opin Investig Drugs. 2021 Apr;30(4):401-409 - PubMed
  66. Curr Diab Rep. 2007 Jun;7(3):175-80 - PubMed
  67. Liver Int. 2019 May;39 Suppl 1:43-62 - PubMed
  68. Ann Oncol. 2018 Sep 1;29(9):1895-1902 - PubMed
  69. Medicines (Basel). 2020 Aug 31;7(9): - PubMed
  70. JAMA Oncol. 2021 May 1;7(5):739-743 - PubMed
  71. Cancer Discov. 2017 Sep;7(9):943-962 - PubMed
  72. Cancer Res. 2009 Sep 15;69(18):7385-92 - PubMed
  73. J Gastroenterol. 2015 Jan;50(1):65-75 - PubMed
  74. Front Genet. 2020 Dec 18;11:614888 - PubMed
  75. PLoS One. 2016 Sep 29;11(9):e0163699 - PubMed
  76. Trends Microbiol. 2004 Feb;12(2):96-102 - PubMed
  77. Lancet. 2018 Mar 24;391(10126):1163-1173 - PubMed
  78. Exp Clin Transplant. 2019 Jun;17(3):363-369 - PubMed
  79. Clin Cancer Res. 2019 Apr 1;25(7):2116-2126 - PubMed
  80. Hepatology. 2021 Jan;73(1):422-436 - PubMed
  81. Ann Surg. 2011 Nov;254(5):824-29; discussion 830 - PubMed
  82. Eur J Cancer. 2019 Apr;111:94-106 - PubMed
  83. Lancet Oncol. 2020 May;21(5):671-684 - PubMed
  84. N Engl J Med. 2018 Feb 22;378(8):731-739 - PubMed
  85. N Engl J Med. 2015 Aug 20;373(8):726-36 - PubMed
  86. J Gastrointest Oncol. 2014 Dec;5(6):428-32 - PubMed
  87. HPB (Oxford). 2015 Aug;17(8):669-80 - PubMed
  88. Nature. 2021 Apr;592(7854):450-456 - PubMed
  89. J Surg Oncol. 2019 Dec;120(8):1358-1364 - PubMed
  90. Cancer Discov. 2017 Oct;7(10):1116-1135 - PubMed
  91. Int J Clin Exp Pathol. 2014 Oct 15;7(11):7890-8 - PubMed
  92. J Transl Med. 2021 Jan 6;19(1):5 - PubMed
  93. Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2097-100 - PubMed
  94. Med Oncol. 2014 Nov;31(11):264 - PubMed
  95. Ann Surg. 2015 Jun;261(6):1173-83 - PubMed
  96. Liver Int. 2015 Mar;35(3):1077-86 - PubMed
  97. Oncol Rep. 2014 Aug;32(2):700-8 - PubMed
  98. BMC Cancer. 2013 Feb 02;13:52 - PubMed
  99. Gastroenterology. 2017 Sep;153(3):812-826 - PubMed
  100. N Engl J Med. 2020 May 14;382(20):1894-1905 - PubMed
  101. Hepatology. 2013 Apr;57(4):1407-15 - PubMed
  102. EXCLI J. 2020 Jun 03;19:718-733 - PubMed
  103. J Gastrointest Oncol. 2016 Dec;7(6):E98-E102 - PubMed
  104. Med Oncol. 2012 Dec;29(4):2793-9 - PubMed
  105. Cancer Discov. 2014 Jun;4(6):730-43 - PubMed
  106. Medicina (Kaunas). 2019 Oct 21;55(10): - PubMed
  107. Lancet Oncol. 2014 Jul;15(8):819-28 - PubMed
  108. Curr Gastroenterol Rep. 2011 Apr;13(2):182-7 - PubMed
  109. N Engl J Med. 2019 Jul 25;381(4):317-327 - PubMed
  110. Dig Surg. 2013;30(4-6):309-16 - PubMed
  111. World J Surg. 2015 Nov;39(11):2748-56 - PubMed
  112. JAMA Surg. 2014 Jun;149(6):565-74 - PubMed
  113. Lancet Oncol. 2012 Feb;13(2):181-8 - PubMed
  114. J Hepatol. 2018 Jul;69(1):182-236 - PubMed
  115. World J Gastroenterol. 2016 Dec 21;22(47):10406-10414 - PubMed
  116. Lancet. 2014 Dec 6;384(9959):2053-63 - PubMed
  117. Clin Cancer Res. 2019 Apr 1;25(7):2021-2023 - PubMed
  118. Int J Biol Markers. 2000 Jul-Sep;15(3):226-30 - PubMed
  119. Br J Cancer. 2011 Jun 28;105(1):131-8 - PubMed
  120. Dig Liver Dis. 2016 Oct;48(10):1227-32 - PubMed
  121. Visc Med. 2016 Dec;32(6):395-400 - PubMed
  122. Clin Cancer Res. 2019 Jul 1;25(13):3753-3758 - PubMed
  123. Ann Oncol. 2015 May;26(5):943-949 - PubMed
  124. Hepatology. 2019 Feb;69(2):622-638 - PubMed
  125. Hepatology. 2018 Sep;68(3):949-963 - PubMed
  126. Ecancermedicalscience. 2014 Nov 06;8:479 - PubMed
  127. Cancer. 2016 Dec 15;122(24):3838-3847 - PubMed
  128. PLoS One. 2020 May 7;15(5):e0232449 - PubMed
  129. Clin Cancer Res. 2017 Jul 15;23(14):3953-3965 - PubMed
  130. J Gastroenterol Hepatol. 2016 Feb;31(2):493-500 - PubMed
  131. Biochim Biophys Acta Rev Cancer. 2020 Dec;1874(2):188451 - PubMed
  132. Pancreatology. 2018 Dec;18(8):862-867 - PubMed
  133. Cancer. 2021 Apr 15;127(8):1293-1300 - PubMed
  134. J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89 - PubMed
  135. J Clin Gastroenterol. 2013 Nov-Dec;47(10):861-70 - PubMed
  136. Nat Rev Gastroenterol Hepatol. 2011 Apr;8(4):189-200 - PubMed
  137. Hepatology. 2018 Sep;68(3):1025-1041 - PubMed
  138. Cancers (Basel). 2020 Nov 15;12(11): - PubMed
  139. CA Cancer J Clin. 2017 Mar;67(2):93-99 - PubMed
  140. BMC Cancer. 2019 Oct 28;19(1):1007 - PubMed
  141. Lancet Oncol. 2021 May;22(5):690-701 - PubMed
  142. Oncotarget. 2017 May 30;8(22):36161-36170 - PubMed
  143. J Hepatol. 2020 Jan;72(1):95-103 - PubMed
  144. Ann Surg Oncol. 2008 Feb;15(2):583-9 - PubMed
  145. Hepatol Res. 2016 Feb;46(2):201-8 - PubMed
  146. Lancet Oncol. 2015 Jul;16(7):859-70 - PubMed
  147. ESMO Open. 2020 Jun;5(3):e000682 - PubMed
  148. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  149. Clin Cancer Res. 2018 Sep 1;24(17):4154-4161 - PubMed
  150. Clin Transl Oncol. 2021 Jan;23(1):82-91 - PubMed
  151. DNA Cell Biol. 2020 Apr;39(4):499-512 - PubMed
  152. Hepatology. 2008 Jul;48(1):308-21 - PubMed
  153. Hum Pathol. 2014 Aug;45(8):1630-8 - PubMed
  154. Am J Gastroenterol. 2007 Oct;102(10):2164-70 - PubMed
  155. Nat Rev Dis Primers. 2021 Jan 21;7(1):6 - PubMed
  156. Gastroenterology. 2012 Apr;142(4):1021-1031.e15 - PubMed
  157. Onco Targets Ther. 2019 Apr 24;12:2981-2988 - PubMed
  158. World J Hepatol. 2020 Dec 27;12(12):1148-1157 - PubMed
  159. N Engl J Med. 2010 Apr 8;362(14):1273-81 - PubMed
  160. Ann Surg. 2013 Jul;258(1):129-40 - PubMed
  161. Oncologist. 2015 Sep;20(9):1019-27 - PubMed
  162. J Clin Oncol. 2011 Aug 10;29(23):3140-5 - PubMed
  163. J Gastroenterol Hepatol. 2011 Nov;26(11):1604-11 - PubMed

Publication Types